Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Gains from Sales and Divestitures (2017 - 2020)

Minerva Neurosciences posted quarterly Gains from Sales and Divestitures of $57075.0 for Q4 2020, down 2.69% year-on-year from $58650.0 in Q1 2020, and up 470.75% on a QoQ basis from $10000.0 in Q3 2020.

Minerva Neurosciences (NERV) has 4 years of Gains from Sales and Divestitures data on file, last reported at $57075.0 in Q4 2020.

  • For the quarter ending Q4 2020, Gains from Sales and Divestitures fell 2.69% year-over-year to $57075.0; the trailing twelve-month figure through Dec 2020 stood at $57075.0 (down 2.69% YoY), and the FY2020 full-year result was $57075.0, down 2.69% from the prior year.
  • Gains from Sales and Divestitures for Q4 2020 stood at $57075.0, up from $10000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $58650.0 in Q4 2018 and bottomed at $10000.0 in Q2 2020.
  • The 4-year median for Gains from Sales and Divestitures is $52862.5 (2017), against an average of $40504.2.
  • The widest annual swing landed in 2018, when Gains from Sales and Divestitures climbed 20.55%; it then slipped 2.69% in 2020.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $48650.0 in 2017, then gained by 20.55% to $58650.0 in 2018, then changed by 0.0% to $58650.0 in 2019, then retreated by 2.69% to $57075.0 in 2020.
  • The last three Gains from Sales and Divestitures figures came in at $57075.0 (Q4 2020), $10000.0 (Q3 2020), and $10000.0 (Q2 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Minerva Neurosciences 215.11 Mn 215.11 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 57,075.00
Dec 31, 2020 57,075.00
Sep 30, 2020 10,000.00
Sep 30, 2020 10,000.00
Jun 30, 2020 10,000.00
Jun 30, 2020 10,000.00
Dec 31, 2019 58,650.00
Dec 31, 2019 58,650.00
Dec 31, 2018 58,650.00
Dec 31, 2018 58,650.00
Dec 31, 2017 48,650.00
Dec 31, 2017 48,650.00